Royalty Pharma Plc Stock Market Value
| RPRX Stock | USD 26.66 0.06 0.23% |
| Symbol | Royalty |
Royalty Pharma Plc Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. If investors know Royalty will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Royalty Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.587 | Dividend Share 0.83 | Earnings Share 2.54 | Revenue Per Share 5.055 | Quarterly Revenue Growth 0.053 |
The market value of Royalty Pharma Plc is measured differently than its book value, which is the value of Royalty that is recorded on the company's balance sheet. Investors also form their own opinion of Royalty Pharma's value that differs from its market value or its book value, called intrinsic value, which is Royalty Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Royalty Pharma's market value can be influenced by many factors that don't directly affect Royalty Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Royalty Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Royalty Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Royalty Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Royalty Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Royalty Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Royalty Pharma.
| 10/31/2024 |
| 11/30/2024 |
If you would invest 0.00 in Royalty Pharma on October 31, 2024 and sell it all today you would earn a total of 0.00 from holding Royalty Pharma Plc or generate 0.0% return on investment in Royalty Pharma over 30 days. Royalty Pharma is related to or competes with Prime Medicine,, Ginkgo Bioworks, Ocean Biomedical, Adaptive Biotechnologies, Ikena Oncology, Ascendis Pharma, and Apellis Pharmaceuticals. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutic... More
Royalty Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Royalty Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Royalty Pharma Plc upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.24) | |||
| Maximum Drawdown | 5.23 | |||
| Value At Risk | (1.62) | |||
| Potential Upside | 1.38 |
Royalty Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Royalty Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Royalty Pharma's standard deviation. In reality, there are many statistical measures that can use Royalty Pharma historical prices to predict the future Royalty Pharma's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.27) | |||
| Treynor Ratio | (6.39) |
Royalty Pharma Plc Backtested Returns
Royalty Pharma Plc maintains Sharpe Ratio (i.e., Efficiency) of -0.11, which implies the firm had a -0.11% return per unit of risk over the last 3 months. Royalty Pharma Plc exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Royalty Pharma's Risk Adjusted Performance of (0.08), variance of 0.9767, and Coefficient Of Variation of (988.66) to confirm the risk estimate we provide. The company holds a Beta of 0.0172, which implies not very significant fluctuations relative to the market. As returns on the market increase, Royalty Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Royalty Pharma is expected to be smaller as well. At this point, Royalty Pharma Plc has a negative expected return of -0.11%. Please make sure to check Royalty Pharma's treynor ratio, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Royalty Pharma Plc performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.76 |
Almost perfect reverse predictability
Royalty Pharma Plc has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Royalty Pharma time series from 31st of October 2024 to 15th of November 2024 and 15th of November 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Royalty Pharma Plc price movement. The serial correlation of -0.76 indicates that around 76.0% of current Royalty Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.76 | |
| Spearman Rank Test | -0.75 | |
| Residual Average | 0.0 | |
| Price Variance | 0.1 |
Royalty Pharma Plc lagged returns against current returns
Autocorrelation, which is Royalty Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Royalty Pharma's stock expected returns. We can calculate the autocorrelation of Royalty Pharma returns to help us make a trade decision. For example, suppose you find that Royalty Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Royalty Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Royalty Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Royalty Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Royalty Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
Royalty Pharma Lagged Returns
When evaluating Royalty Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Royalty Pharma stock have on its future price. Royalty Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Royalty Pharma autocorrelation shows the relationship between Royalty Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Royalty Pharma Plc.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.